Ranger Investment Management L.P. Makes New $9.40 Million Investment in iRadimed Corporation $IRMD

Ranger Investment Management L.P. bought a new position in shares of iRadimed Corporation (NASDAQ:IRMD) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 98,346 shares of the medical equipment provider’s stock, valued at approximately $9,398,000.

Several other large investors have also recently bought and sold shares of the stock. Royal Bank of Canada lifted its position in shares of iRadimed by 14.7% in the first quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock valued at $1,354,000 after buying an additional 3,307 shares during the last quarter. AQR Capital Management LLC increased its position in iRadimed by 7.5% during the first quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock worth $831,000 after acquiring an additional 1,108 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after purchasing an additional 234 shares during the period. Jones Financial Companies Lllp increased its stake in iRadimed by 8,568.5% during the 1st quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock worth $591,000 after acquiring an additional 11,139 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in shares of iRadimed by 1.1% in the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock worth $8,889,000 after purchasing an additional 1,821 shares during the period. 92.34% of the stock is owned by institutional investors and hedge funds.

iRadimed Stock Performance

IRMD opened at $87.85 on Monday. The company has a fifty day moving average price of $93.39 and a two-hundred day moving average price of $94.46. iRadimed Corporation has a 1-year low of $67.84 and a 1-year high of $107.90. The company has a market cap of $1.12 billion, a P/E ratio of 49.08 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. The company had revenue of $20.47 million for the quarter, compared to analysts’ expectations of $20.35 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, research analysts forecast that iRadimed Corporation will post 1.98 EPS for the current fiscal year.

iRadimed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 28th. Shareholders of record on Friday, August 14th will be issued a $0.20 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s dividend payout ratio is presently 44.69%.

Insider Transactions at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.60, for a total value of $226,500.00. Following the completion of the sale, the chief executive officer owned 2,162,500 shares of the company’s stock, valued at approximately $195,922,500. This trade represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 34.60% of the company’s stock.

Analysts Set New Price Targets

IRMD has been the topic of several research analyst reports. Wall Street Zen lowered iRadimed from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings lowered shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $120.00.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.